Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 72 points (0.4%) at 16,112 as of Thursday, Feb. 20, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,810 issues advancing vs. 1,095 declining with 165 unchanged. The Diversified Services industry currently sits up 0.5% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Portfolio Recovery Associates ( PRAA), up 15.8%, and Hertz Global Holdings ( HTZ), up 3.7%. On the negative front, top decliners within the industry include CoStar Group ( CSGP), down 2.7%, ManpowerGroup ( MAN), down 2.7% and Priceline.com ( PCLN), down 0.9%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Myriad Genetics ( MYGN) is one of the companies pushing the Diversified Services industry higher today. As of noon trading, Myriad Genetics is up $1.54 (4.5%) to $35.96 on average volume. Thus far, 1.6 million shares of Myriad Genetics exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $34.20-$36.36 after having opened the day at $34.22 as compared to the previous trading day's close of $34.42. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.6 billion and is part of the services sector. Shares are up 64.1% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate Myriad Genetics a buy, 2 analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Myriad Genetics Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.